A Trial To Study The Effect Of Lamivudine In Adult Patients Who Suffer From Chronic Hepatitis B Alone
A Trial To Study The Effect Of Lamivudine In Adult Patients Who Suffer From Chronic Hepatitis B Alone
The efficacy of lamivudine in Hepatitis Be Antigen (HBeAg) positive Asian patients of chronic
 hepatitis has been well established.The evidence in HBeAg negative patients is limited.
 Limited sustained response was observed post-treatment following a one year treatment period.
 Whether these results can be applied to patients in Iran is uncertain. This study is
 therefore intended to further assess the efficacy profile after two years of open treatment
 in the adult Iranian population.
Inclusion Criteria:

 -  Confirmed active liver disease due to Hepatitis B virus.

 -  Patients must have adequate blood & liver functions.

 -  Female patients of child-bearing potential must be non pregnant and willing to abstain
 from intercourse from 2 weeks prior to administration of the first dose of study
 medication until 28 days after the final dose of study medication or be willing to
 consistently and correctly use an acceptable method of birth control.

 -  Patients who have serious concurrent illnesses other than hepatitis B like cancer,
 severe heart disease, uncontrolled diabetes mellitus or AIDS will not be eligible.

 Exclusion Criteria:

 -  Persons allergic to lamivudine or suffering from hepatitis C, D or E infection or
 taking alcohol will not be eligible.